IPM- Final
-
Upload
khanjan-kotecha -
Category
Documents
-
view
274 -
download
3
Transcript of IPM- Final
Indian Pharmaceutical Market - An Overview
JUN '07 MAT JUN '08 MAT JUN '09 MAT JUN '10 MAT0
5000100001500020000250003000035000400004500050000
3534 4015 37747193
2884132856
36630
43823
Incr. Value ( Rs. Cr.) Value ( Rs. Cr.)
IPM is growing at 19.6%, which is the highest growth since 4 years, with a
CAGR of 15.2%
Total IPM & Incremental Value (in Rs. Cr.) YoY
Val.
(Rs.
Cr.)
1
2
Growth Drivers of IPM
Macroeconomic Environment – Strong GDP growth, Rapid urbanization, Govt. initiatives, changing demographics & development of biologics.
Healthy Environment – Increase private & govt. spending & increase access to lower class towns.
Robust Market Trend – We observe that IPM is on a high growth trend for the past year after a relatively low profile in 2008-09.
3
Chart 4- Growth Drivers Of the IPM
Jun '08 MAT Jun '09 MAT Jun '10 MAT0
5
10
15
20
25
53
1211
1
8
7
7
Vol. Growth% Price-led Growth% NI Growth%
(14)
(11)
(20)
Figures in () indicate value growth of IPM in %
% g
row
th
4
Table 1: Performance of NI over the last 4 years
Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT
Value of IPM (`Cr.) 28,841 32,856 36,630 43,823
No. Of NI 4,810 4,285 4,365 4,562
Value of NI (Cr.) 2,166 2,183 2,438 2,719
Contribution to IPM (%) 7.5 6.6 6.7 6.2
5
Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT
28,84132,856
36,630
43,823
Value of IPM (Cr.)
Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT
4,810
4,2854,365
4,562
No. Of NI
Jun '07 MAT
Jun '08 MAT
Jun '09 MAT
Jun '10 MAT
2,166 2,1832,438
2,719
Value of NI (Cr.)
Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT
7.56.6 6.7
6.2
Contribution to IPM (%)Contribution to IPM (%)
Performance of NI over the last 4 years
6
Jun ‘07 MAT Jun ’08 MAT Jun ’09 MAT Jun ’10 MAT
No. of NIs above Rs. 10 Cr. 10 10 15 20
Value of NIs above Rs. 10 Cr. 135 165 300 438
Contribution of NIs above Rs. 10 Cr. to total NI value 6.2% 7.5% 12.3% 16.1%
Value of largest NIs (Rs. Cr.) 23.3 30.9 52.1 81.4
Table 2: No of NIs above Rs. 10 Cr.
7
Top 10 New Introductions as per ‘JUN 10 MATS. No. Brand Company Sub-group Prod. Launch
YYYY-MMVal
( Rs. Cr.)IPM 2718.9
1 AEROCORT* CIPLA R03CK SALBUTAMOL + BECLOMETHASONE 2008 - 08 81.4
2 A TO Z NS* ALKEM A11A4 OTH. MULTIVIT.-MIN. SOLID 2008 - 11 28.5
3 JANUMET MSD A10BT ANTIDAIBETICS COMBINATIONS (METFORMIN +SITAGLIPTIN)
2008 - 12 27.8
4 MTP KIT CIPLA G03K1 MIFEPRISTON 2009 - 02 26.3
5 GALVUS NOVARTIS A10BE OTHER ANTIDIABETICS-PLAIN (VILDAGLIPTIN)
2008 - 08 26.3
6 MTPROST KIT CIPLA G03K1 MIFEPRISTON 2009 - 02 26.2
7 POLYBION SF* MERCK A11E8 OTH. B-COMP.COMBINATION LIQIUDS
2009 - 06 25.1
8 POLYBION-LC* MERCK A11E8 OTH. B-COMP.COMBINATION LIQIUDS
2009 - 03 20.9
9 NORFLOX-TZ* CIPLA P01A6 TINI+ OTH. COMBINATION SOLID 2008 - 12 20.5
10 JALRA USV A10BE OTHER ANTIDIABETICS-PLAIN (VILDAGLIPTIN)
2009 - 01 19.9
* REFORMULATIONS
8
Insights Among products that were launched New packs/ Reformulations
showed the highest gain. New Introduction by Cipla constituted to 51% amongst top ten
Brands. Demonstrating their success in brand building. Antidiabetics form the major therapy amongst new Introduction,
indicating a strong potential in the segment. Among the top 10 companies in IPM, only Cipla & Alkem are
reflected in top 10 new introductions. 6/10 NI are combinations, thus indicating continued focus on
combination drugs in India Mifepriston brands together account for Rs. 50 Cr. within a year of
launch, thus indicating the huge potential of the contraceptive market
9
Rank (G/L over last year
Brand
Company
Value
(Rs. Cr.)
Incr. Value (Rs. Cr.)
Value Growth %
Jun' 09 MAT Jun'10 MAT
IPM 43,823 7,193 11 20
1(1) Corex Pfizer 204 32 17 19
2(-1) Phensedyl Piramal Healthcare 203 24 17 19
3(0) Voveran Novartis 159 24 6 18
4(3) Augmentin GSK 158 38 10 31
5(0) Human Mixtard 30/70 Abbott 157 32 3 26
6(7) Revital Ranbaxy 152 47 29 45
7(4) Becosules Pfizer 140 30 15 27
8(1) Dexorange Franco Indian 140 26 16 22
9(-1) Zifi FDC 138 23 8 20
10(2) Monocef Aristo Pharma 136 26 24 24
Top 10 brands (Jun’ 10 MAT)
10
INSIGHTS Cipla despite being the no. 1 company does not have a single brand in Top 10 products.
Except for Human Mixtard 30/70 (Abbott)- used for Chronic Therapy, Acute therapy still has a strong foothold in the Top 10 brands.
Corex (204Cr.) & Phensedyl (203Cr.), both cough syrups occupying No.1 & 2 position respectively, are going neck to neck.
Zifi (FDC) & Monocef (Aristo), No.9 & 10 brands respectively, belong to the same class - Cephalosporins.
Zifi with a value growth of 20% in Jun’ 10 MAT compared to 8% in Jun’09 MAT shows positive signs for Sub-class- Cefixime.
Augmentin (GSK) shows the 2nd highest incremental value of Rs.38Cr. even after 30 years of its launch.
11
80 81 81 81
20 19 19 19
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT
MNC's
Indian Companies
Contribution of Indian Companies & MNC’s to IPM
28,841 32,856 36,630 43,823
% c
ontr
ibuti
on
12
INSIGHTS
With MNC’s looking out for Inorganic growth in IPM, the figures are bound to improve for MNC’s in near future.(e.g. Abbott-Piramal)
13
Growth drivers ofIndian Cos.
VsMNCs
14
Jun'08 MAT
Jun'09 MAT
Jun'10 MAT
0
2
4
6
8
10
12
14
16
18
20
52
111
1
09
9
8
Vol growth % Price led growth %NI Growth %
% G
row
th
Jun'08 MAT
Jun'09 MAT
Jun'10 MAT
0
5
10
15
20
25
5 4
152
1
1
5
3
5
Vol Growth %Price led Growth %NI Growth %
% G
row
th
INDIAN COS. MNC
15
Top 10 companies in the IPM
16
Rank(Jan’10 MAT)
Companies Val(Rs. Cr.)
MS (%)
G/L in MS over last year
Incr. value(Rs. Cr.)
Val growth(%)
1. Cipla 2,311 5.3 -0.04 365 19
2. Ranbaxy 2,104 4.8 -0.2 273 15
3. GSK 1,872 4.3 -0.03 295 19
4. Piramal Healthcare
1,835 4.2 -0.03 288 19
5. Zydus Cadila
1,641 3.7 0.1 319 24
6. Sun Pharma
1,625 3.7 0.2 345 27
7. Alkem 1,413 3.2 0.1 258 22
8. Pfizer 1,370 3.1 0.1 245 22
9. Mankind 1,298 3.0 0.3 340 35
10. Abbott 1,243 2.8 0.1 239 24
Top 10 companies in the IPM
17
Growth Drivers of Top companies
Cipla Ranbaxy GSK Piramal Healthcare
Zydus Cadila
Sun Pharma
Alkem Pfizer Mankind Abbott-5
0
5
10
15
20
25
30
35
40
611
17
5
18 16 18 1724
201
-1
1
4
-5
3
-1
3
12 5
1
13
67 9 2
13
1
NI Growth % Price Led Growth % Volume Growth %
(19) (22)(22)(27)
(24)(19)(19)(15)
(24)
(35)
% G
row
th
Figures in () indicate value growth of IPM in %
18
Company Turnover & Growth GridValue Growth (%) Turnover > Rs. 250 Cr. Turnover Rs. 100 - Rs. 250 cr. Turnover Rs.60–
Rs.100Cr.High>20%
Elder Pharma, Mankind, Macleods, Intas, Sun Pharma, MSD, Unichem, Zydus Cadila,
Abbott, Sanofi Aventis, Microlabs, USV, Alkem, DRL, Franco Indian,
Indoco, Pfizer, Merck Ltd, Alembic, Glenmark, Novartis
Hegde & Hegde, Geno, Meyer Organics, Win Medicare, Eli
Lilly, Allergan, Wanbury, Systopic, Orchid Chem &
Pharma, Centaur, Blue Cross, Hetero Healthcare
Troikaa Pharma, Tablets India, Baidyanath, East India, UCB Pharma, TTK
Healthcare Ltd.
Val. Contri.(%) to IPM 42% 4% 1%Medium10-20%
Cipla, GlaxoSmithKline, Piramal Healthcare, Ipca labs, Aristo Pharma, Lupin Ltd., Torrent Pharma, AstraZeneca, FDC,
Ranbaxy, Wockhardt, Emcure, Cadila Pharma
Medley, Apex, Unique Pharma, Janssen Cilag, Jagson
Pal, Wallace, Maneesh Pharma, Fourts India,
Biochem, Raptakos Brett, Modi Mundi Pharma,
Bestochem, Ajanta Pharma, Charak Pharma, Panacea
Biotech, Albert David
Serum Institute, British Biological, Serdia, Walter
Bushnell, Pharmed, Natco Pharma,
Universal, Johnson & Johnson, Anglo French
Drugs
Val. Contri.(%) to IPM 34% 6% 2%Low
<10%Himalaya Drug Shreya Lifescience, CFL,
Dabur, Ind-SwiftBiological E, Bayer Pharma Ltd., Dey S,
Paras, RPG Life SciencesVal. Contri.(%) to IPM 1% 1% 1%
Companies that have moved up the grid, Companies that have moved down the grid, New companies that have entered the grid, Companies that have remained in the same grid
19
ACUTE SEGMENT GROWTH DRIVERS
Jun'08 MAT Jun'09 MAT Jun'10 MAT0
2
4
6
8
10
12
14
16
18
20
3 2
11
88
8
NI growth%Price led growth %Volume led growth%
(12)(11)
(19)
% g
row
th
Figures in () indicate value growth of IPM in %
20
CHRONIC SEGMENT GROWTH DRIVERS
Jun'08 MAT Jun'09 MAT Jun'10 MAT0
5
10
15
20
25
11
6
15
2
2
17
7
7
NI growth%Price led growth %Volume led growth%
% g
row
th
(23)
(14)
(20)
Figures in () indicate value growth of IPM in %
21
Table 7:Top 10 Therapy segments in the
IPM
22
Rank (G/L over last
year)
Therapy
Val. Contri. % Val. Gr. %
No. of NIs
Val/NI (Rs. Cr)
CAGR* (%)
JUN’09 MAT
JUN’10 MAT
JUN’09 MAT
JUN’10 MAT
IPM 36,631(Rs.Cr)
43,823 (Rs.Cr)
11 20 4,562 0.6 15
1 Anti Infectives 17.5 17 9 16 705 0.64 14
2 Cardiac 11.3 11.4 14 21 354 0.54 19
3 Gastro Intestinal 10.9 10.9 11 20 555 0.37 14
4 Respiratory 8.9 8.9 11 20 430 0.65 14
5 Pain/Analgesics 8.7 8.6 10 19 568 0.51 12
6 Vitamins/ Minerals/ Nutrients 7.7 7.8 8 21 361 0.95 12
7 Gynaecology 5.8 5.8 14 20 287 0.71 17
8(+2) Anti Diabetic 5.3 5.7 15 29 116 1.51 23
9 Neuro/CNS 5.5 5.6 13 22 230 0.47 17
10(-2) Derma 5.5 5.5 15 19 337 0.5 15
*Note: CAGR is drawn over a period of 4 years
23
INSIGHTS
Anti Diabetic segment is the fastest growing and most promising segment and most important growth driver for IPM.
All chronic therapies (>20%) are contributors while most acute therapies (<20%) are dilutors to the growth of IPM.
There is high emphasis on New Introductions which is a key to growth of IPM with the average value/NI increasing for most therapies.
24
Chart 10: Growth drivers of Top 10
Therapy segments in the IPM
25
Chart10:Growth drivers of Top 10 Therapy segments in IPM
IPM
Anti Infecti
ves
Cardiac
Gastro In
testinal
Respira
tory
Pain/Analgesic
s
Vitamins/M
inerals/Nutri
ents
Gynaecology
Anti Diabetic
Neuro/C
NS
Derma
-5
0
5
10
15
20
25
30
35
12 1217
139 8 7 8
18 1510
1
-3
22 2 2 3
22
1
7 75
58 9 12 9
9
5
8
Vol.Growth% Price led Growth% NI Growth%
% G
row
th
(16)(21) (21)
(19)(22)
(20)(20) (20)
(29)
(20) (19)
Figures in () indicate value growth of IPM in %
26
INSIGHTS
Anti Diabetic and Cardiac segments have shown tremendous volume growth which reflects the potential of chronic therapy in today’s market.
Anti Infective segment has shown negative price led growth due to price reduction which is indicative of high competition in this segment.
IPM is driven by volume and NI growth rather than price led growth which is indicative of a healthy industry and good future prospects.
27
Anti-infectives Therapy
28
Company Val.(Rs. Cr.)
Mkt. Share
(%)
Val. Gr.
(%)
Brands > Rs. 10 Cr. Top Brand Value of Top
Brand (Rs. Cr.)No. Value
(Rs. Cr.)
Contri. To
Portfolio (%)
Anti-infectives 7,467 100 16 160 4,772 64 AUGMENTIN 158
RANBAXY (1) 760 10.2 13 16 650 85 MOX 126
ALKEM (2) 715 9.6 15 15 571 80 TAXIM 133
ARISTO PHARMA (3) 503 6.7 22 7 422 84 MONOCEF 136
CIPLA (4) 464 6.2 19 10 316 68 NOVAMOX 85
GLAXOSMITHKLINE (5) 416 5.6 23 6 391 94 AUGMENTIN 158
Top 5 companies in the Anti-infectives Therapy MarketFigures in ( ) indicate rank as per Jun ‘ 09 MAT
• Augmentin (GSK) being the top brand in the Anti-infectives segment, Ranbaxy still holds No.1 position.• Value growth of GSK has been the highest at 23%.
29
760
715503
464
416
Ranbaxy (1)Alkem (2)Aristo pharma (3)Cipla (4)GSK (5)
(10.2 %)
(9.6%)
(6.7%)
(6.2%)
(5.6%)
Value (Rs. Cr.)of Top 5 Companies in the Anti-infectives Therapy Market
Rank as per Jun ‘ 09 MAT
Anti-infectives Val. (Rs. Cr.) = 7,467Figures in ( ) indicate Market Share (%)
30
Cardiac Therapy
31
CompanyVal(Rs. Cr)
MrktShare(%)
ValGr.
(%)
Brands > Rs. 10 Cr
Top Brand
Value ofTop
Brand(Rs. Cr)
No.Value
(Rs. Cr)
Contri to Portfolio
(%)
CARDIAC 5006 100 21 123 2769 55 STORVAS 97
Sun Pharma (2) 329 6.6 27 11 213 65 AZTOR 39
Torrent Pharma (1) 317 6.3 18 9 191 60 DILZEM 47
Zydus Cadila (3) 301 6.0 22 6 212 70 ATEN 82
Unichem (6) 286 5.7 28 6 181 63 LOSAR-H 63
Cipla (4) 275 5.5 17 6 147 53 AMLOPRES 44
Top 5 Companies in the Cardiac Therapy Market
Figures in ( ) indicate rank as per Jun ’09 MAT
32
Insights0 Storvas is the top brand in Cardiac segment but Ranbaxy
does not feature in top 5 companies.0 Sun Pharma, with a bigger product basket (11 Brands)
leads the market.0 Storvas and Aztor both are among the top brands thus
indicating good acceptance of dyslipidaemics in the market.
0 With Dilzem, Aten and Amlopres featuring in top 5 brands, is indicative of good anti anginal therapy market.
0 The top 3 companies have managed to remain in the top positions since last year.
0 Unichem has shown a high growth rate and has moved up to number 4.
33
Gastro Intestinal Therapy
34
CompanyValue(Rs. Cr.)
Mkt Share
(%)
Value Growth
(%)No.
Brands>10 Cr
Top Brand
Value of Top Brand(Rs. Cr.)
Value (Rs. Cr.)
Contri. to portfolio
(%)
Gastro Intestinal 4771 100 20 103 2687 56 Zinetac 99
ABBOTT (1) 291 6.1 18 9 265 91 Digene 92
ZYDUS CADILA (2) 265 5.6 24 7 194 73 Ocid 52
DRL (3) 231 4.8 23 6 193 84 Omez 92
ALKEM (5) 213 4.5 38 5 158 74 Pan 59
MANKIND (6) 198 4.1 29 3 62 31Zenflox-
OZ28
Top 5 companies in the Gastro Intestinal Therapy Market
Figures in ( ) indicate rank as per Jun ’09 MAT
35
Insights
0 Zinetac is the top brand in GI segment but GSK does not feature in top 5
0 Mankind with just 3 brands greater than 10 crores has made it top 5
0 Ocid, Omez and Pan are among the top brand thus indicating good acceptance of PPI in the market.
0 Abbott has 91% brands above 10 crores, possibly the reason why it is placed at the top in GI category
0 The top 3 companies have managed to maintain their positions since last year
0 Alkem has shown a high growth rate and has moved up a spot to number 4
36
Respiratory therapy Market
37
Table 11: Top 5 Companies in Respiratory Therapy Market
Company Value (Rs cr.)
Mkt Share
(%)
Val. Growth
(%)Brands > Rs10 cr Top Brand
Value of top brand
(Rs. Cr.)
No. Value (Rs. Cr)
Contribution to portfolio(%)
Respiratory 3895 100 20 72 2258 58 Corex 204
Cipla 715 18.4 16 13 553 77 Asthalin 126
Piramal 311 8 15 4 277 89 Phenesedyl Cough 203
Pfizer 249 6.4 23 2 223 89 Corex 204Zydus Cadila 173 4.4 23 3 102 59 Deriphylline 62
GSK 168 4.3 9 6 115 69 Cetzine 41
38
INSIGHTS
0 Companies having a Value growth of more than 20 % are the growth drivers of respiratory segment.
0 Pfizer and Zydus Cadila are the growth drivers among top 5 companies.
0 Pfizer and Piramal Healthcare are highly vulnerable because of their high dependence on one brand in their portfolio (89%)
0 Top 5 companies in Respiratory segment contribute to 40% of market.
39
Anti-Diabetic Therapy Market
40
Company Value (Rs. Cr.)
Market Share
(%)Growth
(%) No.
Brands > Rs. 10 crore
Top brandValue of
Top Brand (Rs. Cr.)
Value (Rs. Cr.)
Contri. To portfolio
(%)
Anti Diabetic 2500 100 29 63 1614 65 Human Mixtard 30/70 157
Abbott (1) 442 17.7 20 10 393 89 Human Mixtard 30/70 157
USV (2) 272 10.9 30 9 231 85 Glycomet 66
Sanofi Aventis (3) 199 7.9 31 5 184 93 Lantus 68
Sun Pharma (4) 175 7 28 6 138 79 Glucored 45
Eli Lilly (5) 113 4.5 23 3 85 76 Huminsulin 30/70 63
Figures in ( ) indicate rank as per Jun ’09 MAT
Top 5 companies in the Anti-diabetic Therapy Market
41
Top companies in Each Zone
42
TOP COMPANIES IN EACH ZONESRANK IPM NORTH EAST WEST SOUTH
1 CIPLA CIPLA ALKEM CIPLA RANBAXY
2 RANBAXY RANBAXY GSK PIRAMAL (1) CIPLA
3 GSK PIRAMAL PIRAMAL (1) ZYDUS (2) SUN
4 PIRAMAL GSK RANBAXY(-1) GSK (-2) GSK
5 ZYDUS MANKIND SUN PFIZER (2) ZYDUS
6 SUN ZYDUS ZYDUS (1) RANBAXY (-2) ABBOTT (1)
7 ALKEM LUPIN CIPLA (-1) EMCURE (-1) PIRAMAL (-1)
8 PFIZER PFIZER ALEMBIC (2) SUN (1) DRL (1)
9 MANKIND (2) ALKEM (2) ARISTO FDC (-1) MICROLABS (-1)
10 ABBOTT SUN PFIZER (-2) MANKIND (3) PFIZER
43
INSIGHTS
0 Market leader Cipla is doing well in most markets except east
0 Similarly Ranbaxy is doing well in most markets except west, and Piramal in south
0 Companies such as Microlabs and Dr Reddy’s laboratories have a grip on south market only, and are not in top ten in other markets.
44
Top 10 co. across town classes
45
Rank Metro Class I Class II-VI Rural1 Ranbaxy Cipla Cipla Cipla
2 Cipla RanbaxyPiramal
HealthcarePiramal
Healthcare3 Sun Pharma GSK GSK GSK
4 Zydus CadilaPiramal
HealthcareRanbaxy Mankind
5 Pfizer Zydus Cadila Mankind Ranbaxy 6 GSK Sun Pharma Alkem Alkem
7Piramal
HealthcareAlkem Zydus Cadila Zydus Cadila
8 Sanofi Aventis Lupin Sun Pharma Aristo Pharma9 Abbott Pfizer Aristo Pharma Pfizer
10 Lupin Abbott Pfizer Abbott
Top 10 companies across Companies
GSK has a stronger hold in Class I-IV & Rural areas than in Metro Pfizer & Abbott trying to penetrate the class I-IV & Rural market Growing presence of MNCs can be seen in rural areas
46
Hospital Segment Performance
47
Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
93 93 92 91
7 7 8 9
HAS SSA
% C
on
trib
uti
on
(14) (11) (20)
(16) (12) (21) (37)
Rs. 31,173 Cr. Rs. 35,464 Cr. Rs. 39,786 Cr.
Rs. 48,136 Cr.
(14)
Contribution of SSA and HSA in the IPMFigures in ( ) are value growth %
48
Hospital Segment Performance
0 Hospital segment has registered a robust value growth of 37% (Jun 10 MAT) as compared to last year’s 21% (Jun 09 MAT).
0 Hospital segment contributed 9% to the total IPM (SSA + HAS) as per Jun’10 MAT.
0 The trend for past 4 years showed an upward trend in this contribution from Jun’07 MAT to Jun’10 MAT, which supports the fact that Hospital sector is gaining importance in the IPM and as a result more players are strengthening their focus towards this sector.
0 In terms of growth, Hospital sales showed high growth of 37% growth as per Jun’10 MAT
49
Top Companies in Hospital Market
HSA rank Jun ‘10 MAT (HSA rank Jun ‘07 MAT)
Company Value ( Rs. Cr.)
Val Gr. ( %)
IPM 4,313 37
1 (1) GlaxoSmithKline 251 35
2 (6) Sun Pharma 240 60
3 (2) Cipla 228 44
4 (5) Zydus Cadila 189 39
5 (3) Pfizer 189 57
6 (9) Piramal Healthcare 180 44
7 (4) Sanofi Aventis 178 48
8 (8) Ranbaxy 165 46
9 (10) Lupin Limited 156 39
10 (7) Alkem 137 16
50
Insights
0 There is a considerable shift in the ranks of companies in the hospital segment
0 Sun pharma, Sanofi Aventis and Alkem has the greatest had the greatest change in the ranking.
51
RankTherapy
Value contribution(%) Value growth (%)CAGR (%)(G/L) over
last year)June ‘09
MATJune ‘10
MATJune ‘09
MATJune ‘10
MAT
IPM 3155 Crs 4313 Crs 21 37 23
1 Anti infectives 26.8% 25.6% 18 30 20
2 Cardiac 11.11% 11.8% 19 45 25
3 Gastro intestinal
8.3% 8.1% 21 34 19
4 Pain/Analgesics
7.4% 7.2% 21 33 22
5 Gynaec 6.0% 5.9% 26 34 21
6 Respiratory 5.9% 5.6% 38 30 29
7(+1) Neuro/CNS 5.0% 5.4% 29 49 31
8 (-1) Vitamins/Minerals/Nutrients
5.1% 5.0% 18 32 18
9 Others 4.3% 4.9% 11 57 31
10 Anti diabetic 3.5% 4.1% 21 58 35
Top therapies in hospital market
52
Insights
0 All the top 10 therapies have recorded a robust double digit growth i.e. more than 30% growth.
0 Neuro and CNS increased the contribution by 0.4%0 New introductions added an incremental value of Rs.
300 Cr. which constitutes 26% of the total incremental value.
53
Specialty Rx contribution%
Jun ‘ 09 MAT Jun ‘10 MAT
All Specialties 156 crs 164 crs
General practitioners
40.2% 40.1%
Mass specialties 28.6 % 28.6%
Super specialties 31.1% 31.3%
Specialty – wise prescription split
54
General p
racti
tioners
Mass sp
ecialit
ies
Super specia
lities
0
10
20
30
40
50
60
70
62.712
44.61648.516
65.764
46.90451.332
Jun '09 MATJun'10 MAT
All specialties
Rx contri-bution
Highest Rx contribution was obtained from general practitioners . In Jun’10 general practitioners added more number of prescriptions (3.1cr).
55
Therapies Rx contribution %
Total Rx (Rs. Cr.)
G.P.Total Super specialties
Mass specialties
Total 164 40% 31% 29%
Anti infective 63 50% 24% 26%
Cardiac 9 20% 42% 38%
Gastro intestinal 51 43% 26% 31%
Respiratory 37 49% 18% 33%
Pain/analgesics 61 40% 36% 25%
Vitamins / Minerals / Nutrients 30 38% 28% 35%
Gynecology 11 30% 12% 58%
Anti Diabetic 4 14% 42% 44%
Neuro / CNS 11 21% 53% 27%
Derma 9 34% 36% 30%
Top therapies in IPM
56
Anti infective
Pain / analgesics
Gastro intestinal
Respiratory
Vitamins/ Minerals / Nutrients
Gynaecology
Neuro / CNS
Derma
Cardiac
Anti Diabetic
0 10 20 30 40 50 60 70
63
61
51
37
31
11
11
9
9
4
Total Rx in cr.
Total Rx in cr.
Therapies
Currently , anti infective therapy is the growth driver of IPM
57
GPs - highest prescription contribution: Anti infective therapy
Super specialties - highest prescription contribution: neuro/CNS therapy
Mass specialties - highest prescription contribution: Gynaecology
Anti infective
Respiratory
Gastro intestinal
Pain / Analgesics
Vitamins / Minerals / Nutrients
Derma
Gynaecology
Neuro / CNS
Cardiac
Anti Diabetic
0% 10%20%30%40%50%60%70%
Mass specialties
Super specialties
G.P.
Rx contribution %
58
Rank CompaniesRx contribution (%)
Jun '09 MAT Jun '10 MAT
IPM 156 Cr. 164 Cr.
1 (1) GSK 10.8% 10.7%
2 (2) Cipla 10.1% 9.9%
3 (4) Mankind 8.1% 9.2%
4 (3) Piramal Healthcare 8.9% 8.8%
5 (5) Zydus Cadila 7.1% 7.1%
6 (6) Ranbaxy 7.0% 6.7%
7 (7) DRL 6.6% 6.6%
8 (8) FDC 6.1% 5.9%
9 (9) Alkem 5.3% 5.6%
10 (11) Sun Pharma 4.7% 4.9%
Figures in ( ) are value growth %
Top co. in IMS Rx Audit
Total IPM = 43823 Cr.
Total Rx IPM = 164 Cr.
Rx IPM contributes to 0.3% of total
IPM
Indicating a heavy trend of OTX selling in
India
59
Top co. in Prescription Audit
0 Rx IPM contributes to 0.3% of total IPM (Jun ‘10 MAT)
0 The total contribution of Rx to IPM is low. Indicating a heavy trend of OTX.
0 GSK & Cipla have managed to be doctor’s favorite while prescribing.
0 Mankind has grown by leaps and bound each year even in Rx market. Indicating good acceptance among doctors.
0 GSK is the only MNC that features among the top 10 (Assumption: Piramal & Ranbaxy started as Indian and later acquired by MNC)
Insights
60
June '10 MATRx contri (%) Rxber contribution (%)
Total 164 Cr. 244000GP Total 66 Cr. 94000GP (Non MBBS) 65% 69%GP (MBBS) 35% 32%MASS SPECIALITIES 47 Cr. 65000Gynaecologist 27% 34%CP 30% 28%Paediatrician 28% 23%Gen. Surgeon 14% 16%SUPER SPECIALITIES 51 Cr. 85000Dentist 29% 33%Orthopaedic 12% 12%Opthamologist 9% 11%ENT Specialist 8% 8%Cardiologist 6% 7%Dermatologist 6% 6%Chest TB Specialist 4% 5%Neurologist Neuro Surgeon 3% 5%Nephrologist Urologist 3% 4%Diabetologist Endocrinologist 3% 3%Psychiatrist 3% 3%Gastroenterologist 3% 3%Oncologist 1% 2%
Prescription & Prescriber Dispersion
61
Prescription & Prescriber Dispersion
Insights
0 Max. prescribers are GP (Non MBBS) – Might indicate patients price sensivity towards Doctor’s fees.
0 Top 3 Rxber contribution(1) GP (Non-MBBS) (2) Gynaecs (3) Dentists
0 Barring dentists the overall superspeciality size is comparitively smaller.
62
Indian Vaccine Market - An Overview
63
Total IPM & Incremental Value (in Rs. Cr.) YoY
Val. (
Rs.
Cr.
)
Indian Pharmaceutical Market - An Overview
Source: IMS – June’10 MAT
19.6% Gr ,highest since 4 years, CAGR- 15.2%
64
(>>) (-2)
(24)
(53)Va
l. (R
s. C
r.)
June MAT
Growth double
than last year
Vaccine Market - Trend
Source: IMS – June’10 MATFig ( ):% Val Gr
Vaccine Market:
Business Channels
65
(10)
(41)
(48)
(53)
(-27)(96)
(>>)
(19)
Source: IMS – June’10 MATFig ( ):% Val Gr
Dispensing doctors & Hospitals drive market
Vaccine Market:Indian Vs MNCs
66
(27)
(21) (38)
(64)
Source: IMS – June’10 MATFig ( ):% Val Gr
MNCs drive
market
Vaccine Market: Top 10 Companies
67
Rank June’10
MAT
Company Val.(Rs. Cr.)
Market Share %
Val. Growth %
Vaccine Market 726 100% 53
1 GSK 131 18% 23
2 Sanofi Aventis 129 18% >>
3 Pfizer 71 10% 75
4 Novartis 68 9% -12
5 Serum Institute 68 9% 40
6 Panacea Biotech 59 8% 57
7 VHB Lifesciences 33 5% >>
8 Zydus Cadila 32 4% 56
9 MSD 31 4% >>
10 Shantha Biotech 24 3% 15
Top 10 contributes
90%
Vaccine Market :Top Therapies
Therapies Value (Rs. Cr.)
Share % Val. Grwth % Incr. Val. (Rs. Cr.)
June’09 MAT
June’10 MAT
June’09 MAT
June’10 MAT
Vaccine Market
726.1 100% 24 53 93 250
Toddler Vaccine
211 29% 55 60 47 79
Adult Vaccine
205 28% -4 22 -7 37
Paediatric Combination Vaccines
146 20% 67 >> 28 77
Paediatric Single Vaccines
131 18% 25 32 20 32
All Other Vaccines
33 5% --- 431 6 2768
Vaccine Market: Top 10 Brands Rank
June’10 MAT
Brands Company Val.(Rs. Cr.)
Val. Growth % Incr. val. (Rs. Cr.)
June’09 Mat
June’10 MAT
June’09 Mat
June’10 MAT
Vaccine Market
726 24 53 93.1 250
1 Prevenar Pfizer 71 150 75 24 30
2 Rabipur Novartis 68 4 -12 3 -9
3 Pentaxim Sanofi Aventis
46 >> >> 7 39
4 Havrix GSK 37 9 47 2 12
5 Varivax VHB 33 59 >> 5 18
6 Vaxirab Zydus Cadila 32 -11 56 -3 11
7 Varil Rix GSK 25 -3 -9 -1 -2
8) Gardasil MSD 22 ---- >> 5 16
9 Verorab Sanofi Aventis
21 ---- ---- 0 21
10 Rotarix GSK 21 ---- >> 10 11
69
Top 10 contributes
--50%
Vaccine Market : Top 10 NIS
NIs Comapny Launch Date
YYYY MM
Value(Rs. Cr.)
Incr. Val.(Rs. Cr.)
Vaccine Market 104 79
Gardasil MSD 2008 10 22 16
Rotarix GSK 2008 07 21 11
Pentavac Serum Institute 2008 10 16 12
Cervarix GSK 2009 02 11 10
Polprotec Panacea Biotech 2008 07 9 6
Xprab RANBAXY 2009 10 7 7
Quadrovax Serum Institute 2008 11 4 3
Comvac- 5 Bharat Biotech 2009 02 3 3
Pentavac - SD Serum Institute 2009 11 2 2
Shan HIB- DPT Shantha Biotech
2008 09 2 170
NIs 7.55% contr,